Gilead Sciences, Inc. (NASDAQ:GILD) Director John Francis Cogan sold 5,833 shares of the business’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $80.09, for a total transaction of $467,164.97. Following the sale, the director now owns 58,452 shares in the company, valued at $4,681,420.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
John Francis Cogan also recently made the following trade(s):
- On Monday, March 12th, John Francis Cogan sold 5,833 shares of Gilead Sciences stock. The stock was sold at an average price of $80.93, for a total transaction of $472,064.69.
Gilead Sciences stock opened at $76.49 on Thursday. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. The stock has a market capitalization of $100,762.73, a P/E ratio of 21.98, a P/E/G ratio of -1.77 and a beta of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same period in the prior year, the company posted $2.70 earnings per share. equities analysts anticipate that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a $0.57 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 annualized dividend and a dividend yield of 2.98%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio is presently 65.52%.
GILD has been the topic of a number of recent research reports. Citigroup upgraded shares of Gilead Sciences from a “neutral” rating to a “buy” rating and cut their price target for the stock from $88.80 to $76.00 in a research note on Tuesday, January 30th. Royal Bank of Canada reiterated a “buy” rating and set a $94.00 price target on shares of Gilead Sciences in a research note on Friday, February 23rd. BMO Capital Markets upped their target price on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock a “market perform” rating in a research note on Thursday, February 8th. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price on the stock. in a research note on Wednesday, January 17th. Finally, Credit Suisse Group lowered shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and upped their target price for the stock from $74.35 to $80.00 in a research note on Wednesday, December 20th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences has an average rating of “Buy” and a consensus price target of $88.61.
Hedge funds have recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after acquiring an additional 258,005 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of Gilead Sciences by 26.6% in the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after acquiring an additional 100,741 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after acquiring an additional 2,148,697 shares during the period. Northern Trust Corp boosted its holdings in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after acquiring an additional 116,780 shares during the period. Finally, Toronto Dominion Bank boosted its holdings in shares of Gilead Sciences by 19.0% in the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after acquiring an additional 75,364 shares during the period. 77.83% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “John Francis Cogan Sells 5,833 Shares of Gilead Sciences, Inc. (GILD) Stock” was originally posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.thelincolnianonline.com/2018/03/22/john-francis-cogan-sells-5833-shares-of-gilead-sciences-inc-gild-stock-2.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.